All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Risk factors associated with high-risk patients with PV: An update from IACH 2024
Bookmark this article
|
During the 7th Annual Meeting of the IACH, Alvarez-Larrán discussed factors that should be considered in the risk stratification of patients with PV.1 Risk factors associated with the complications of high-risk PV, such as arterial/venous thrombosis, increased bleeding, and disease progression, were also discussed.1 |
| Key learnings |
| High-risk patients with PV are stratified based on age >60 years, a history of arterial/venous thrombosis, persistent leukocytosis, and inadequate hematocrit control with phlebotomies. |
| Risk factors associated with arterial thrombosis include the history of arterial thrombosis, age >60 years, cardiovascular risk factors, and TET2/DNMT3A mutations. Risk factors related to venous thrombosis include JAK2V617F VAF >50% and an NLR >5. |
| Extreme thrombocytosis and AVWD (VMF <30%) are associated with increased bleeding. |
| JAK2V617F VAF >50%, TP53 mutations, and chromatin/spliceosome mutations have been linked with disease progression to MF or AML. |
| A personalized approach that considers individual risk factors may be needed in the stratification and management of patients with high-risk PV. |
Abbreviations: AML, acute myeloid leukemia; AVWD, acquired von Willebrand disease; IACH, International Academy for Clinical Hematology; MF, myelofibrosis; VAF, variant allele frequency; VMF, von Willebrand factor; WBC, white blood cell.
- Alvarez-Larrán A. What is a high-risk PV patient in 2024? Presented at: 7th Annual Meeting of the International Academy for Clinical Hematology; Sep 19-21, 2024; Paris, FR.
Your opinion matters
29 votes - 3 days left ...
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox